BioSpace News Archive

Researchers have identified several factors that should help improve the diagnosis of chronic nonbacterial osteomyelitis, also known as chronic recurrent multifocal osteomyelitis.

Since doctors began treating cancer patients with immunotherapy drugs called checkpoint inhibitors nearly a decade ago, they have observed that a subset of these patients experience a side effect that clinically looks like inflammatory arthritis.

Pharmaron Beijing Co. announced that it has acquired 100% of the equity of Absorption Systems for up to US$137.5 million in cash.

The global hip replacement implants market is estimated to be driven by rise in geriatric population and augmented demand for hip arthroplasty/replacement surgical procedures.

The medical device manufacturing industry is rapidly growing across the globe and along with that contract manufacturing services form a large part of the industry.

Calliditas Therapeutics AB announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Ascentage Pharma announced that the results from two pivotal Phase II studies of the company’s novel BCR-ABL inhibitor, HQP1351, have been accepted for oral presentation at the 62nd American Society of Hematology Annual Meeting.

Liminal BioSciences Inc. announced that the U.S. Food and Drug Administration has notified the Company that it has extended the review period for the Biologics License Application for Ryplazim®, or Ryplazim, for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency.

3D printed wearables are an amazing fusion of technology, fashion, and healthcare. The evolutionary drive for 3D printed wearables market has stemmed from the vast capabilities that wearable hold.